Beleave Supports Recent Council Decision and Continues Expansion Uninterrupted

TORONTO, Nov. 10, 2017 -- Beleave Inc. (“Beleave”) (CSE:BE) (OTCQX:BLEVF) strongly supports The City of Hamilton council’s decision to turn down the motion for any new restrictions pertaining to the land use planning framework for the cannabis industry.  The company continues to move forward with its facility expansion in the community of Flamborough, in the city of Hamilton, Ontario, for which it has engaged Havecon North America Inc., subsidiary of Havecon Kassenbouw, a leading Dutch-based greenhouse builder.

“Since locating in Flamborough we have been dedicated to working with the City of Hamilton to develop a framework that has allowed for a mutually beneficial relationship,” commented Beleave COO Bill Panagiotakopoulos, “We will continue to offer our full support to ensure we are all putting our best foot forward together.”

A motion proposing certain land-use planning restrictions aimed at the cannabis sector was tabled on October 11^th, 2017.  Following consultations with local Licensed Producers and other stakeholders, the motion was withdrawn by a vote of twelve representatives to three.  The decision underpins the company’s belief that Hamilton is a strong and vibrant economy to base its operations.

The city, like many across the country, will continue to review the framework for the cannabis industry which is natural given the infancy of the sector as a whole.

About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.

For more information contact:

Sebastian de Kloet
Phone: 1 (905) 979 - 5173      
Email: [email protected]